Empowering Blue Zones
For Referring Physicians
A medically led cross-border referral pathway for selected orthopaedic degenerative and neurological cases where
non-surgical intervention is being considered. Designed for clinics in Dubai, Hong Kong, and Singapore referring
patients for triage, treatment planning, and short-stay rehabilitation in Bali.
This page is intended for healthcare professionals. Final candidacy and treatment decisions are made by the treating
medical team in Indonesia under applicable regulations and clinical governance.
Orthopaedic degenerative indications
Neurology-related indications (selected)
High-priority exclusion/red-flag screen| Domain | What to provide | Why it matters |
|---|---|---|
| Clinical diagnosis | Working diagnosis, severity, duration, and current functional limitations. | Supports indication fit and realistic outcome planning. |
| Prior treatment history | Conservative care attempted (medication, PT, injections, rehab) and response quality. | Clarifies non-surgical treatment context before referral. |
| Imaging and investigations | Recent imaging reports and key laboratory findings relevant to risk screening. | Reduces repeat workup and accelerates triage decisions. |
| Risk and safety profile | Comorbidities, current medications, anticoagulation status, allergy profile. | Improves treatment safety planning and peri-procedural decisions. |
| Patient goals | Primary functional goals (pain, mobility, ADLs, return-to-work/sport expectations). | Aligns intervention plan with measurable, patient-specific outcomes. |
Indonesia has increasingly structured regenerative medicine pathways under national regulation. This referral journey
is coordinated with established local partners, including collaboration with Murni Teguh Hospital in Bali, conveniently located close to Ngurah Rai International Airport (view on map), for international patient coordination and specialist review.
Where indicated and permitted under applicable Indonesian frameworks, approved single-line MSC-based protocols may
be considered by the treating team. Treatment is never guaranteed and remains indication-driven, risk-adjusted, and
physician-supervised.
Murni Teguh Hospital in Bali is the clinical facility partner and service location for this referral pathway. Official hospital website: https://www.rsmurniteguh.com/id/HospitalGroup/murni-teguh-tuban-bali. Located near the international airport, it provides the hospital setting for specialist review, treatment delivery, and post-procedure monitoring. Treatment eligibility and protocols are determined by the treating medical team under prevailing regulatory and clinical governance requirements.
The stem cells used in this pathway are Umbilical Cord Mesenchymal Stem Cells (UCMSCs) manufactured by Regenic, a subsidiary of Kalbe Farma and one of Indonesia’s largest pharmaceutical groups. Official Regenic website: https://www.regenic.co.id/en.
The facility uses single-line MSC protocols, meaning cells are derived from a single donor source and expanded under controlled conditions. This reduces batch variability and helps lower immunological risk compared with pooled multi-donor products, improving product consistency and traceability.
No. Primary referral intent should be a clinically defined medical condition where regenerative intervention is
being considered after standard evaluation. Anti-aging or aesthetics are secondary and not the primary reason
for treatment selection.
Include diagnosis summary, prior treatment attempts and outcomes, relevant imaging/labs, medication list, risk
profile, and clear functional goals. This enables faster multidisciplinary suitability review.
Referring clinics receive triage feedback, treatment summary, discharge recommendations, and follow-up guidance.
The local treating team and referring physician coordinate ongoing care decisions after return.
For doctors and clinics keen to join: every Saturday at 11:00 AM Dubai / 3:00 PM SGT. Please submit your details and preferred Saturday below.
Compliance note: This content is informational for healthcare practitioners and does not replace
independent clinical judgment, local regulatory requirements, or informed consent standards. Treatment suitability
and outcomes vary by patient profile and indication.